Safety profile of pharmacotherapy in paitionts with non-alcogolic fatty liver disease
https://doi.org/10.21518/2079-701X-2019-3-69-75
Abstract
NAFLD is a leader among chronic liver diseases worldwide. Polymorbidity of such patients requires the appointment of different groups of drugs. The quality of pharmacological correction, which is determined in achieving the desired therapeutic effect and the absence of adverse reactions of the therapy, depends on the functional state of the liver. In diseases of the liver clearance of drugs is reduced, and the period of their half-life increases. Thus, drugs with high hepatic extraction may increase the risk of overdose. In this connection, prior to therapy, laboratory and instrumental control of liver function is necessary to reduce the risk of its drug damage, side effects of pharmacotherapy and prevention of complications.
About the Authors
E. I. Peresada
Federal State Budgetary Institution «Almazov National Medical Research Center» of the Ministry of Health of the Russian Federation;
Federal State Budgetary Military Educational Institution of Higher Education «Military Medical Academy named after S.M. Kirov» of the Ministry of Defense of the Russian Federation
Russian Federation
Russian Federation
postgraduate student of the department of laboratory medicine and genetics, 197341, St. Petersburg, Akkuratova St., 2;
lecturer of the department of military toxicology and medical protection, 194044, Saint-Petersburg, 6, Akademika Lebedev Street
P. V. Seliverstov
Federal State Budgetary Educational Institution of Higher Education «Mechnikov North-Western State Medical University» of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
MD, Ph.D., assistant professor of department internal medicine and nephrology North-Western State Medical University of Mechnikov,
191015, St. Petersburg, Kirochnaya St., 41
T. V. Vavilova
Federal State Budgetary Institution «Almazov National Medical Research Center» of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
MD, рrofessor, head of the department of laboratory medicine and genetics,
197341, St. Petersburg, Akkuratova St., 2
V. A. Basharin
Federal State Budgetary Military Educational Institution of Higher Education «Military Medical Academy named after S.M. Kirov» of the Ministry of Defense of the Russian Federation
Russian Federation
Russian Federation
MD, Professor, head of the department of military toxicology and medical protection,
194044, Saint-Petersburg, 6, Akademika Lebedev Street
V. G. Radchenko
Federal State Budgetary Educational Institution of Higher Education «Mechnikov North-Western State Medical University» of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
MD, professor of department internal medicine and nephrology,
191015, St. Petersburg, Kirochnaya St., 41
References
1. Bezvulyak E.I., Melnichnikova O.S., Vavilova T.V. Optimizing monitoring of everolimus levels in patients after heart transplantation against the background of hepatopathy. Eksperimental’naya i Klinicheskaya Gastroenterologiya. 2018;2:68-73. (In Russ).
2. Bezvulyak E.I., Vavilova T.V., Basharin V.A. Pharmacological and laboratory aspects of therapeutic drug monitoring of everolimus. Medline.ru. 2018;19(29):292-406. (In Russ).
3. World Gastroenterological Organization. Global practical guidelines «Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis». 2012. www.worldgastroenterology.org. (In Russ).
4. European Association for the Study of the Liver, European Association for the Study of Diabetes and the European Association for the Study of Obesity. «Clinical guidelines of EASL – EASD – EASO for the diagnosis and treatment of non-alcoholic fatty liver disease». Journal of Hepatology. 2016;64:1388–1402. (In Russ).
5. Drapkina O.M., Korneeva O.N. Continuum of non-alcoholic fatty liver disease: from liver steatosis to cardiovascular risk. Smezhnye Problemy Kardiologii. 2016;12(4):424- 429. (In Russ).
6. Lazebnik L.B., Radchenko V.G., Golovanova E.V., Zvenigorodskaya L.A., Konev Yu.V., Seliverstov P.V., Sitkin S.I., Tkachenko E.I., Aylamazyan E.K., Vlasov N.N., Kornienko E.A., Novikova V.P., Horoshinina L.P., Zhestkova N.V., Oreshko L.S., Dudanova O.P., Dobritsa V. .P., Turyeva L.V., Tirikova O.V., Kozlova N.M, et al. Non-alcoholic fatty liver disease: clinical presentation, diagnosis, treatment. The guidelines were approved by the 15th Congress of NOGR in 2015. Eksperimental’naya i Klinicheskaya Gastroenterologiya. 2015;7(119):85-96. (In Russ).
7. Suchkova E.V. Non-alcoholic fatty liver disease: clinical and laboratoryinstrumental features of the liver and biliary tract function, the efficacy of combination therapy. Dissertation for the degree of candidate of medical sciences. 2017 (In Russ).
8. Tirikova O.V., Kozlova N.M., Eliseev S.M. et al. Non-alcoholic fatty liver disease and its role in the development of cardiovascular diseases. Sibirsky Meditsinsky Zhurnal. 2015;1:30-36. (In Russ).
9. Kobalava J.D., Shavarova E.K., Malaya I.P. Features of pharmacokinetics and drug doseranging in patients with impaired liver function. Klinicheskaya Farmakologiya i Terapiya. 2010;19(2):40-47. (In Russ).
10. Mikheeva O.M. Liver and drug metabolism. Eksperimental’naya i Klinicheskaya Gastroenterologiya. 2011;1:121-124. (In Russ).
11. Minushkin O.N. Hepatoprotectors in the treatment of certain liver diseases. Meditsinsky Sovet. 2016;14:52- 57. (In Russ).
12. Sitkin S.I., Vakhitov T.Ya., Tkachenko E.I., Lazebnik L.B., Oreshko L.S., Zhigalova T.N., Radchenko V.G., Avalueva E.B., Seliverstov P.V., Utsal V.A., Komlichenko E.V. Microbial and endogenous metabolic disorders in ulcerative colitis and celiac disease: a metabolic approach to identifying potential biomarkers of chronic inflammation in the intestine associated with dysbiosis. Eksperimental’naya i Klinicheskaya Gastroenterologiya. 2017;7(143):4-50. (In Russ).
13. Seliverstov P.V. Non-alcoholic fatty liver disease: from theory to practice. Arkhiv Vnutrennei Meditsiny. 2015;1(21):19-26. (In Russ).
14. Promenasheva T.E., Kolesnichenko L.S., Kozlova N.M. The role of oxidative stress and glutathione system in the pathogenesis of non-alcoholic fatty liver disease. Acta Biomedica Scientifica. 2014;5(99):80-83. (In Russ).
15. Radchenko V.G., Shabrov A.V., Zinovyeva E.N., Sitkin S.I. Bile duct and liver diseases. SPb., 2011. 526 p. (In Russ).
16. Seliverstov P.V., Prikhodko E.M., Sitkin S.I., Radchenko V.G., Vakhitov T.Ya., Shavarda A.L. The role of intestinal microbiocenosis and microbiota exometabolites disorders in the development of non-alcoholic fatty liver disease. Gastroenterologiya St. Petersburga. 2016;3-4:M21-M22. (In Russ).
17. Seliverstov P.V. Obesity as a risk factor for the development of cardiovascular complications on the background of nonalcoholic fatty liver disease. Meditsinsky Almanakh. 2016;1(41):61–3. (In Russ).
18. Trukhan D.I., Ivanova D.S. Non-alcoholic fatty liver disease associated with obesity: therapeutic options. Consilium Medicum. 2016;18(8). (In Russ).
19. Chirkin A.A. Molecular mechanisms of liver injury. Immunopathologiya, Allergologiya, Infektologiya. 2000;1:27-34. (In Russ).
20. Khalilulin T.R., Garmash I.V., Malaya I.P. Clinical and pharmacological studies in patients with impaired liver function. Klinicheskaya Farmakologiya i Terapiya. 2012;21(2):30-33. (In Russ).
21. Bradley J.A., Watson C.J.E. MTOR inhibitors: Sirolimus and Everolimus. Kidney transplantation. 2013;19:267-286.
22. Brea A., Puzo J. Non-alcoholic fatty liver disease and cardiovascular risk. Int J Cardiol. 2013;167(4):1109-17.
23. Clayton T.A. et al. Pharmacometabonomic identification of a significiant host-microbiome metabolic interaction affecting human drug metabolism. PNAS USA. 2009;106:14728-14733.
24. Lida N. et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Scince. 2013;342:967- 970.
25. Predicting and mainpulatiing cardiac drug inactivation by the human gut bacterium Eggerthella Lenta. Scince. 2013;341:295-298.
26. Targher G., Marra F., Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia. 2008;51(11):1947-1953.
27. Viaud S. et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Scince. 2013;342:971-976. 28. Wallace B.D. et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Scince. 2010;330:831-835.
Review
For citations:
Peresada EI, Seliverstov PV, Vavilova TV, Basharin VA, Radchenko VG. Safety profile of pharmacotherapy in paitionts with non-alcogolic fatty liver disease. Meditsinskiy sovet = Medical Council. 2019;(3):69-75. (In Russ.) https://doi.org/10.21518/2079-701X-2019-3-69-75
Views:
668
Email this article 